The stream of companies undergoing inversions will continue until the U.S. moves to territorial taxation coupled with a lower U.S. corporate tax rate, said Tim Larson, Partner-in-Charge of Tax & Business Services at Marcum. Larson said he does not expect Congress to take such a large step anytime soon so companies, especially in the pharmaceutical sector, will continue to try and redomecile abroad. Larson said tax inversion is not a new strategy for companies seeking a competitive advantage because it was prevalent in the energy sector 20-30 years ago. Finally, Larson said he expects technology companies to follow the path of pharma firms because they have fewer tangible assets abroad, but lots of cash.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst